Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yardena Samuels

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Cancer Cell|February 14, 2018
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in MelanomaYong Yu, Kolja Schleich, Bin Yue, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
Temporal genomic analysis of melanoma rejection identifies regulators of tumor immune evasionSapir Cohen Shvefel, Joy A Pai, Yingying Cao, et al.
Nature Genetics|March 31, 2009
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanomaLavanya H Palavalli, Todd D Prickett, John R Wunderlich, et al.
Cell|September 17, 2019
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in MelanomaYochai Wolf, Osnat Bartok, Sushant Patkar, et al.
Cell Reports. Medicine|December 17, 2025
Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentationShira Sagie, Tomer Babu, Chen Weller, et al.
Nature Genetics|October 27, 2015
Recurrent inactivating RASA2 mutations in melanomaRand Arafeh, Nouar Qutob, Rafi Emmanuel, et al.
Nature|December 17, 2020
Anti-tumour immunity induces aberrant peptide presentation in melanomaOsnat Bartok, Abhijeet Pataskar, Remco Nagel, et al.
Cancer Discovery|September 14, 2018
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in MelanomaShelly Kalaora, Yochai Wolf, Tali Feferman, et al.
Nature Cancer|May 22, 2023
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLCAaron Javitt, Merav D Shmueli, Matthias P Kramer, et al.
Cancer Cell|December 19, 2015
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ DepletionKensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Cancer Cell|February 14, 2018
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in MelanomaYong Yu, Kolja Schleich, Bin Yue, et al.
Biorxiv : the Preprint Server for Biology|December 11, 2023
Temporal genomic analysis of melanoma rejection identifies regulators of tumor immune evasionSapir Cohen Shvefel, Joy A Pai, Yingying Cao, et al.
Nature Genetics|March 31, 2009
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanomaLavanya H Palavalli, Todd D Prickett, John R Wunderlich, et al.
Cell|September 17, 2019
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in MelanomaYochai Wolf, Osnat Bartok, Sushant Patkar, et al.
Cell Reports. Medicine|December 17, 2025
Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentationShira Sagie, Tomer Babu, Chen Weller, et al.
Nature Genetics|October 27, 2015
Recurrent inactivating RASA2 mutations in melanomaRand Arafeh, Nouar Qutob, Rafi Emmanuel, et al.
Nature|December 17, 2020
Anti-tumour immunity induces aberrant peptide presentation in melanomaOsnat Bartok, Abhijeet Pataskar, Remco Nagel, et al.
Cancer Discovery|September 14, 2018
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in MelanomaShelly Kalaora, Yochai Wolf, Tali Feferman, et al.
Nature Cancer|May 22, 2023
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLCAaron Javitt, Merav D Shmueli, Matthias P Kramer, et al.
Cancer Cell|December 19, 2015
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ DepletionKensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, et al.
Pageof 11